OPEN END TURBO LONG - GILEAD SCIENCES | Real-time Bid/Ask 09:08:19 19/06/2024 BST | ||
| 1.15 EUR / 1.27 EUR | +7.08% |
|
| Current month | -5.83% | ||
| 1 month | -25.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 18/06/24 | 1.13 | -11.72% |
| 17/06/24 | 1.28 | -3.03% |
| 14/06/24 | 1.32 | +13.79% |
| 13/06/24 | 1.16 | -0.85% |
| 12/06/24 | 1.17 | -6.40% |
Delayed Quote Börse Stuttgart
Last update June 18, 2024 at 08:42 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Morgan Stanley |
| WKN | MC19H2 |
| ISIN | DE000MC19H20 |
| Date issued | 23/04/2019 |
| Strike | 50.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.11 € |
|---|---|
| Lowest since issue | 0.76 € |
| Spread | 0.12 € |
| Spread % | 9.45% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
63.15
USD
Average target price
82.7
USD
Spread / Average Target
+30.95%
- Stock Market
- Certificates
- Certificat